Propel Bio Management, LLC
An institutional investment manager in Los Angeles, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 13, 2026. SEC CIK 1969764.
- Reported value$191.1m
- Positions29
Holdings: 29 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Plains GP Holdings LP-CLPAGP | COMM | 72651A207 | 30.9 | 16.2% | 1,272,360 | Unchanged | |
| Achieve Life Sciences IncACHV | COMM | 004468500 | 26.3 | 13.8% | 4,034,018 | Added+247,593 | |
| Corcept Therapeutics IncCORT | COMM | 218352102 | 11.9 | 6.2% | 136,499 | Reduced−11,329 | |
| Phathom Pharmaceuticals IPHAT | COMM | 71722W107 | 11.4 | 6.0% | 1,050,358 | Added+209,086 | |
| Delcath Systems IncDCTH | COMM | 24661P807 | 11.0 | 5.7% | 871,460 | Reduced−108,238 | |
| Milestone PharmaceuticalsMIST | COMM | 59935V107 | 10.0 | 5.2% | 7,429,590 | Added+3,311,269 | |
| Compass Pathways plcCMPS | ADRS | 20451W101 | 8.1 | 4.2% | 573,086 | Reduced−168,963 | |
| Kyverna Therapeutics IncKYTX | COMM | 501976104 | 7.9 | 4.1% | 883,198 | Added+238,777 | |
| Artiva Biotherapeutics inARTV | COMM | 04317A107 | 6.8 | 3.5% | 696,436 | Added+550,067 | |
| Abeona Therapeutics IncABEO | COMM | 00289Y206 | 6.1 | 3.2% | 983,070 | Reduced−346,829 | |
| Aquestive Therapeutics inAQST | COMM | 03843E104 | 6.0 | 3.1% | 1,442,397 | Added+731,409 | |
| Palisade Bio IncPALI | COMM | 696389402 | 5.4 | 2.8% | 2,582,388 | Added+1,467,388 | |
| Immunic IncIMUX | COMM | 4525EP200 | 5.0 | 2.6% | 325,022 | New+325,022 | |
| Inventiva SA - AdrIVA | COMM | 46124U107 | 4.8 | 2.5% | 1,281,212 | Added+556,534 | |
| SAB Biotherapeutics IncSABS | COMM | 78397T202 | 4.2 | 2.2% | 1,076,578 | Added+63,788 | |
| Orchestra Biomed HoldingsOBIO | COMM | 68572M106 | 3.9 | 2.0% | 896,701 | Unchanged | |
| Celldex Therapeutics IncCLDX | COMM | 15117B202 | 3.9 | 2.0% | 103,695 | Reduced−27,669 | |
| Zevra Therapeutics IncZVRA | COMM | 488445206 | 3.6 | 1.9% | 253,544 | Reduced−28,874 | |
| Ocular Therapeutix IncOCUL | COMM | 67576A100 | 3.5 | 1.8% | 357,966 | Reduced−24,409 | |
| 4D Molecular Therapeutics inFDMT | COMM | 35104E100 | 3.4 | 1.8% | 252,654 | Reduced−127,766 | |
| Ovid Therapeutics IncOVID | COMM | 690469101 | 3.0 | 1.6% | 1,115,538 | Added+194,081 | |
| Eyepoint IncEYPT | COMM | 30233G209 | 2.7 | 1.4% | 191,745 | Reduced−24,080 | |
| Upstream Bio IncUPB | COMM | 91678A107 | 2.4 | 1.3% | 350,389 | Added+8,610 | |
| Scynexis IncSCYX | COMM | 811292309 | 2.2 | 1.2% | 543,478 | New+543,478 | |
| Silence Therapeutics plcSLN | ADRS | 82686Q101 | 2.1 | 1.1% | 191,733 | New+191,733 | |
| Leonabio IncLONA | COMM | 04746L203 | 1.4 | 0.7% | 149,279 | Unchanged | |
| Maze Therapeutics IncMAZE | COMM | 578784100 | 1.3 | 0.7% | 43,798 | Unchanged | |
| Corvus Pharmaceuticals IncCRVS | COMM | 221015100 | 1.1 | 0.6% | 70,380 | Reduced−15,411 | |
| Sagimet Biosciences Inc-ASGMT | COMM | 786700104 | 1.0 | 0.5% | 125,878 | New+125,878 |
Sold out: 13 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Aldeyra Therapeutics IncALDX | COM | 01438T106 | 0.0 | 0.0% | 0 | Sold out−730,606 | |
| Coherus Oncology IncCHRS | COM | 19249H103 | 0.0 | 0.0% | 0 | Sold out−1,420,550 | |
| Connect Biopharma Holdings Ltd | SHS | G23549101 | 0.0 | 0.0% | 0 | Sold out−209,493 | |
| Evommune IncEVMN | COM SHS | 30054Y107 | 0.0 | 0.0% | 0 | Sold out−55,664 | |
| Immunic Inc | COM | 4525EP101 | 0.0 | 0.0% | 0 | Sold out−2,344,779 | |
| Kalaris Therapeutics IncKLRS | COM | 482929106 | 0.0 | 0.0% | 0 | Sold out−295,771 | |
| Nuvation Bio IncNUVB | COM CL A | 67080N101 | 0.0 | 0.0% | 0 | Sold out−329,296 | |
| Oculis Holding AG | ORDINARY SHARES | H5870P102 | 0.0 | 0.0% | 0 | Sold out−122,223 | |
| Satellos Bioscience IncMSLE | COM | 80401L803 | 0.0 | 0.0% | 0 | Sold out−10,145 | |
| Trevi Therapeutics IncTRVI | COM | 89532M101 | 0.0 | 0.0% | 0 | Sold out−223,802 | |
| Uniqure NV | SHS | N90064101 | 0.0 | 0.0% | 0 | Sold out−104,772 | |
| Viridian Therapeutics IncVRDN | COM | 92790C104 | 0.0 | 0.0% | 0 | Sold out−210,163 | |
| VOR Biopharma IncVOR | COM NEW | 929033207 | 0.0 | 0.0% | 0 | Sold out−314,543 |
Source: SEC EDGAR, Form 13F-HR, accession 0001829126-26-008753 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.